ATLANTA -- The Centers for Disease Control and Prevention (CDC) has added laboratory criteria for evidence of infection with the SARS-associated coronavirus (SARS-CoV) to its interim surveillance case definition. CDC Director Dr. Julie L. Gerberding announced a new category, laboratory-confirmed, at a Senate committee hearing on SARS on Tuesday.
A total of 274 cases of SARS have been reported in the United States; 222 are suspect cases and 52 are probable. Of the 52 probable SARS cases reported as of April 29, 2003, 6 are laboratory-confirmed using the new laboratory criteria. Twelve cases are considered probable, but are not laboratory-confirmed, either because the laboratory tests are not sensitive enough to pick up the SARS virus or because the illness was not caused by SARS virus. Laboratory results are undetermined for the remaining 34 probable cases; for some, testing is in progress and for others suitable specimens are not available for testing.
Using the new laboratory criteria, a SARS case is laboratory-confirmed if one of the following is met:
· Detection of antibody to SARS-CoV by indirect fluorescent antibody (IFA) or enzyme-linked immunosorbent assay (ELISA)
· Isolation of SARS-CoV in tissue culture
· Detection of SARS-CoV RNA by reverse transcriptase-polymerase chain reaction (RT-PCR), which must be confirmed by a second PCR test
Negative laboratory results for PCR, viral culture, or antibody tests obtained within 21 days of illness do not rule out coronavirus infection. In these cases, an antibody test of a specimen obtained more than 21 days after illness begins is needed to determine infection.
Most U.S. cases of SARS continue to be associated with travel; a small number of cases have resulted from secondary spread to household members or healthcare workers. CDC will continue to update the SARS case definition as new data become available, or if there are changes in the spread of SARS illness in the United States.
Source: CDC
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.